Original Article

You have full text access to this OnlineOpen article

Potential mediators of the mortality reduction with zoledronic acid after hip fracture

  1. Cathleen S Colón-Emeric1,*,
  2. Peter Mesenbrink2,
  3. Kenneth W Lyles1,
  4. Carl F Pieper1,
  5. Steven Boonen3,
  6. Pierre Delmas4,
  7. Erik F Eriksen5,
  8. Jay Magaziner6

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.090704

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 91–97, January 2010

Additional Information

How to Cite

Colón-Emeric, C. S., Mesenbrink, P., Lyles, K. W., Pieper, C. F., Boonen, S., Delmas, P., Eriksen, E. F. and Magaziner, J. (2010), Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res, 25: 91–97. doi: 10.1359/jbmr.090704

Author Information

  1. 1

    Duke University Medical Center and the Durham VA Geriatrics Research Education and Clinical Center, Durham, NC, USA

  2. 2

    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

  3. 3

    Katholieke Universiteit Leuven, Leuven, Belgium

  4. 4

    Claude Bernard University, Lyon, France

  5. 5

    Novartis Pharma AG, Basel, Switzerland

  6. 6

    School of Medicine, University of Maryland, Baltimore, MD, USA

*Box 3003 DUMC, Durham, NC 27710, USA.

Publication History

  1. Issue published online: 20 JAN 2010
  2. Article first published online: 14 DEC 2009
  3. Manuscript Accepted: 1 JUL 2009
  4. Manuscript Revised: 6 MAY 2009
  5. Manuscript Received: 12 MAR 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (101K)

References

  • 1
    Tosteson A, Gottleib D, Radley D, Fisher E, Melton LR. Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int. 2007; 18: 1463–1472.
  • 2
    Robbins J, Biggs M, Cauley J. Adjusted mortality after hip fracture: from the Cardiovascular Health Study. J Am Geriatr Soc. 2006; 54: 1885–1891.
    Direct Link:
  • 3
    Magaziner J, Lydick E, Hawkes W, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health. 1997; 87: 1630–1636.
  • 4
    Vestergaard P, Rejnmark L, Mosekilde L. Has mortality after a hip fracture increased? J Am Geriatr Soc. 2007; 55: 1720–1726.
    Direct Link:
  • 5
    Lyles K, Colón-Emeric C, Magaziner J, et al. for the HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fracture and mortality after hip fracture. N Engl J Med. 2007; 357: 1799–1809.
  • 6
    Cauley J, Thompson D, Ensrud K, Scott J, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11: 556–561.
  • 7
    Beloosesky Y, Hendel D, Weiss A, et al. Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J Gerontol A Biol Sci Med Sci. 2007; 62: 420–426.
  • 8
    Chuang D, Power SE, Dunbar PR, Hill AG. Central nervous system interleukin-8 production following neck of femur fracture. Aust NZ J Surg. 2005; 75: 813–816.
    Direct Link:
  • 9
    Miller RR, Shardell MD, Hicks GE, et al. Association between interleukin-6 and lower extremity function after hip fracture: the role of muscle mass and strength. J Am Geriatr Soc. 2008; 56: 1050–1056.
    Direct Link:
  • 10
    Onuoha GN, Alpar EK. Elevation of plasma CGRP and SP levels in orthopedic patients with fracture of neck of femur. Neuropeptides. 2000; 34: 116–120.
  • 11
    Svensén CH. Vascular endothelial growth factor (VEGF) in plasma increases after hip surgery. J Clin Anesth. 2004; 16: 435–439.
  • 12
    Tsangari H, Findlay DM, Kuliwaba JS, Atkins GJ, Fazzalari NL. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone. 2004; 35: 334–342.
  • 13
    Zgoda M, Gorecki A, Bartlomiejczyk I, Sieminska J, Chmielewski D, Paczek L. Femoral neck fracture is accompanied by local changes in the content of transforming growth factor-beta1, interleukin-1β and collagenase activity. J Musculoskel Neuronal Interact. 2007; 7: 161–165.
  • 14
    Conti L, Casetti R, Cardone M, et al. Reciprocal activating interaction between dentritic cells and pamidronate-stimulated γδ T cells: role of CD86 and inflammatory cytokines. J Immunol. 2005; 174: 252–260.
  • 15
    Maksymowych W. Bisphosphonates: anti-inflammatory properties. Curr Med Chem. 2002; 1: 15–28.
  • 16
    Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-α and IL-6. J Interferon Cytokine Res. 2003; 23: 649–654.
  • 17
    Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002; 8: 1080–1084.
  • 18
    Bottle A, Aylin P. Mortality associated with delay in operation after hip fracture. BMJ. 2006; 332: 947–951.
  • 19
    Farhat G, Strotmeyer E, Newman A, et al. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study. Calcif Tissue Int. 2006; 79: 102–111.
  • 20
    Tuominen O, Ylitalo-Heikkala R, Vehmas T, Mucha I, Ylitalo P, Riutta A. Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. Methods Find Exp Clin Pharmacol. 2006; 28: 361–367.
  • 21
    Steinbuch M, D'Agostino RB, Mandel JS, et al. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol. 2002; 35: 320–326.
  • 22
    Fisher A, Southcott E, Srikusalanukul W, et al. Relationships between myocardial injury, all-cause mortality, vitamin D, PTH and biochemical bone turnover markers in older patients with hip fractures. Ann Clin Lab Sci. 2007; 37: 222–232.
  • 23
    Black D, Delmas P, Eastell R, et al., for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.
  • 24
    Dobrucali A, Tobey NA, Awayda MS, et al. Physiological and morphological effects of alendronate on rabbit esophageal epithelium. Am J Physiol Gastrointest Liver Physiol. 2002; 283: G576–G586.
  • 25
    Shao W, Orlando RC, Awayda MS, Shao W, Orlando RC, Awayda MS. Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action. Am J Physiol Cell Physiol. 2005; 289: C248–256.
  • 26
    Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study [see comment]. BMJ. 2008; 336: 813–816.
  • 27
    Wehren L, Hawkes W, Orwig D, Hebel J, Zimmerman S, Magaziner J. Gender differences in mortality after hip fracture: the role of infection. J Bone Miner Res. 2003; 18: 2231–2237.
    Direct Link:
  • 28
    Hamel P, Abed E, Brissette L, Moreau R. Characterization of oxidized low-density lipoprotein-induced hormeses-like effects in osteoblastic cells. Am J Physiol. 2008; 294: C1021–1033.
  • 29
    Miller R, Cappola A, Shardell M, et al. Persistent changes in interleukin-6 and lower extremity function following hip fracture. J Gerontol. 2006; 61: 1053–1058.
  • 30
    Schultzberg M, Lindberg C, Aronson A, Hjorth E, Spulber S, Oprica M. Inflammation in the nervous system: physiological and pathophysiological aspects. Physiol Behav. 2007; 92: 121–128.
  • 31
    Marsland A, Petersen K, Sathanoori R, et al. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom Med. 2006; 68: 895–903.
View Full Article (HTML) Get PDF (101K)